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Brachydactyly in Humans via Increased NOTCH Signaling
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Stanley F. Nelson,2 Simon Cool,1 Osama H. Ababneh,3 Azmy Al-Hadidy,3 Amira Masri,3
Hanan Hamamy,4 and Bruno Reversade1,5,*
We delineated a syndromic recessive preaxial brachydactyly with partial duplication of proximal phalanges to 16.8 Mb over 4 chromo-
somes. High-throughput sequencing of all 177 candidate genes detected a truncating frameshift mutation in the gene CHSY1 encoding
a chondroitin synthase with a Fringe domain. CHSY1 was secreted from patients’ fibroblasts and was required for synthesis of
chondroitin sulfate moieties. Noticeably, its absence triggered massive production of JAG1 and subsequent NOTCH activation, which
could only be reversed with a wild-type but not a Fringe catalytically dead CHSY1 construct. In vitro, depletion of CHSY1 by RNAi knock-
down resulted in enhanced osteogenesis in fetal osteoblasts and remarkable upregulation of JAG2 in glioblastoma cells. In vivo, chsy1
knockdown in zebrafish embryos partially phenocopied the human disorder; it increased NOTCH output and impaired skeletal,
pectoral-fin, and retinal development. We conclude that CHSY1 is a secreted FRINGE enzyme required for adjustment of NOTCH
signaling throughout human and fish embryogenesis and particularly during limb patterning.Introduction
Precise diagnosis of brachydactylies, defined by the short-
ening of fingers and/or toes, is often difficult because of
their vast diversity and partial clinical overlap. Five main
types of brachydactylies, termed brachydactyly (BD) types
A– E (MIM 112500, MIM 112600, MIM 112700, MIM
112800, MIM 112900, MIM 112910, MIM 113000, MIM
113100, MIM 113200, MIM 113300, MIM 112440, and
MIM 607004), are classified according to which metacar-
pals and/or metatarsals, phalanges, and digits are affected.1
At the molecular level, extracellular components of two
signaling pathways, BMP/GDF and Hedgehog, have been
shown to cause shortening of digits in humans. Defective
BMP/GDF signaling accounts for BDA2, BDB, and BDC
and can be caused by mutations in the genes encoding
the extracellular BMP antagonist NOGGIN (MIM
602991), the BMP ligand GDF5 (MIM 601146), BMP2
(MIM 112261), and the BMP receptors BMPR1B (MIM
603248) and ROR2 (MIM 602337).2–6 The Hedgehog
pathway accounts for BDA1, which is caused by mutations
in the ligand IHH (MIM 600726), and mutations in SHH
(MIM 600725) cause triphalangeal thumb–polysyndactyly
syndrome (MIM 174500).7,8 Recently, mutations in the
extracellular ligand PTHLH (MIM 168470) were found to
be responsible for BDE, which can also be caused by
HOXD13 (MIM 142989) mutations.9,10
Here we report on the genetic etiology of a syndromic
recessive preaxial brachydactyly caused by a loss-of-func-
tion mutation in the evolutionarily conserved gene
CHSY1 (MIM 608183). CHSY1 encodes a type II transmem-
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functional experiments carried out in patients’ cells,
human fetal osteoblasts cells, and gliobastoma cells
revealed remarkable NOTCH upregulation in the absence
of CHSY1 activity. Knockdown of chsy1 in developing
zebrafish embryos was able to partially phenocopy the
human disorder: it enhanced Notch signaling and
impaired skeletal and pectoral-fin development while
triggering dramatic retinal overgrowth. Taken together,
our results identify an additional layer of control in the
genetic pathway that operates in the vertebrate developing
limb. Our data also suggest that CHSY1, because of its
FRINGE activity, might represent another class of extracel-
lular modulators of NOTCH signaling.Material and Methods
Patients and Clinical Assessment
The affected children were initially diagnosed at the National
Center for Diabetes, Endocrinology & Genetics in Jordan by
Prof. Hanan Hamamy. Genomic DNA from saliva samples
(Oragene, Canada) from the five members of this kindred and
skin biopsies from one affected sibling (II:2) and his unaffected
sister (II:1) were obtained after parents gave their informed
consent and the local ethics commission gave its approval.Genotyping and Homozygosity Mapping
To performhomozygosity and identity-by-descent (IBD)mapping,
we analyzed the SNP chip data of the affected and unaffected
siblings by using custom programs (B. Merriman) written in the
Mathematica (Wofram Research) data-analysis software. In brief,
we determined candidate IBD homozygous blocks in an individualtics, David Geffen School of Medicine, University of California, Los Angeles,
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as follows: using the Illumina 610k SNP Chip (Human610-
Quadv1_B) genotype data, we used AB genotypes to define bound-
aries of homozygous blocks. Blocks that were larger than 2 cM in
size were classified as candidate IBD homozygous blocks. Centi-
Morgan distances between SNPs were determined from the
HapMap Phase II recombination rate map. Regions of identity
(both alleles inherited IBD) between pairs of siblings were deter-
mined in a similar pedigree-free fashion. The final exclusion
mapping that allowed us to obtain candidate disease loci was per-
formed by mathematical manipulation of the various intervals
defined by homozygosity and identity mapping. Specifically, we
defined candidate disease loci as those thatwere homozygous iden-
tical by descent in affected siblings, identical by descent between
affected siblings, and not identical by descent for unaffected
siblings. We obtained candidate disease loci by taking the mathe-
matical intersection of the intervals of homozygosity and identity,
respectively, and then the mathematical complement of these by
the intervals of identity between affected-unaffected sibling pairs.Capture of Genomic Loci
In brief, custom arrays (Agilent 244K) were designed to target
every exonic sequence of the genes present in the four
homozygous indentical-by-descent regions (chr3: 147266776–
155630168; chr5: 168552990–174355393; chr12: 18663–545927;
and chr15: 99141618–100314150), excluding the highly repeated
regions. In total, 1009 contigs encompassing 320,677 bp were
targeted. DNA library for one affected subject was prepared accord-
ing to the Illumina library generation protocol version 2.3 and was
hybridized to the custom arrays according to the Agilent CGH
244K array protocol, then washed, eluted, and amplified. The
sample was submitted to one channel of Illumina flowcell
and sequenced by Illumina Genome Analyzer (GAII) according
to the standard manufacturer’s protocol. The image data were
processed by the provided GA Pipeline (Firecrest version 1.3.4
and Bustard version 1.3.4), and all sequences were aligned to the
human reference genome (UCSC build 18) by Blat-like Fast
Accurate Search Tool (BFAST). We filtered mismatches to
identify variants that were seen ten or more times and that did
not overlap with a known dbSNP129 entry polymorphism. Non-
synonymous mutations were identified with additional SeqWare
tools and the ‘‘knownGene’’ gene model from the UCSC hg18.
The open-source SeqWare project that provides a LIMS tool for
tracking samples (SeqWare LIMS) and a pipeline for sequence anal-
ysis (SeqWare Pipeline) was used throughout this work.Mutation Analysis
Positional candidate genes were obtained from the GenBank and
Ensembl databases. Genes were analyzed by direct sequencing of
DNA with primers flanking each exon. Primer sequences were
based on the reference sequences of each gene. The primer
sequences for CHSY1 (NM_014918.4) and HTLF (NM_002158.3)
mutation screening are given in Table S4. Sequence analysis was
done with the BigDye Terminator cycle sequencing kit (Applied
Biosystems, Foster City, CA), and products were run on a 3730
DNA Analyzer (Applied Biosystems, Foster City, CA).Cell Culture
Primary human skin fibroblasts were cultivated in DMEM (Lonza)
supplemented with 10% fetal calf serum (FCS) (Lonza). Human
fetal osteoblast (hFOB) cells were obtained from ATCC (USA)
and maintained in Ham’s F12 DMEM supplemented with 10%The AmericanFCS and 0.3 mg/ml G418 (Invitrogen, USA) at 33.5C. Human
gliobastoma (T98G) cells were obtained from ATCC (USA) and
maintained in EMEM (ATCC) supplemented with 10% FCS. Inhi-
bition of g-secretase activity was carried out by incubation of cells
with 2 or 5 mM of g–secretase inhibitor X (Calbiochem, 565771)
added fresh daily for 72 hr.
RNA Interference
hFOB and gliobastoma cells were seeded at 20,000 cells/cm2 in
6-well plates and transfected via Lipofectamine 2000 (Invitrogen,
USA) with two siRNAs specific for humanCHSY1 (25 pmol of each)
or scrambled siRNA as a negative control. The siRNAs were
purchased from QIAGEN (Germany), and their sequence is given
in Table S4. For Taqman realtime PCR, cells were assayed 48 or
72 hr after transfection.
Quantitative PCR
RNA was isolated from patients’ fibroblasts, T98G cells, and hFOB
cells by the Trizol (Invitrogen) method. RNA (1 mg) was reverse
transcribed with the Revert Aid kit (Fermentas) and random
hexamers. Quantitative PCR was performed with Taqman probes
(Applied Biosystems). Primers, ABI probes, assay IDs, and
sequences are given in Table S4.
Statistical Analysis
Each experiment was repeated at least three times, and data were
expressed as means 5 SE. Differences among treatments were
analyzed by a Student’s t test. Significant differences were consid-
ered to be those with a p value of < 0.05.
Immunoblot Analysis
Supernatant fractions were obtained after incubation of primary
skin fibroblasts in Pro293a-CDM conditioning serum-free media
(BioWhittaker) for 72 hr. Cells were lysed in RIPA extraction
buffer. Electrophoresis of samples in SDS polyacrylamide gels
with or without DTT was followed by transfer on PVDF
membranes. The following antibodies were used for probing
immunoblots: mouse anti-ACTIN (Chemicon; Mab1501R), rat
anti-NOTCH2 (Developmental Studies Hybridoma Bank;
C651.6DbHN), goat anti-JAG1 (Santa Cruz Biotechnology; sc-
6011), goat anti-HES1 (R&DSystems; AF3317), and rabbit anti-
CHSY1 (Proteintech; 14420-1-AP).
Immunohistochemistry Analysis
For immunostaining, skin biopsies were fixed in 4% (weight/
volume) paraformaldehyde in 13 PBS and embedded in wax,
and sections of 5 mm were placed on coverslips. A mouse mono-
clonal antibody against Chondroitin Sulfate (Sigma; CS-56) was
incubated for 1 hr in 10% normal goat serum at room temperature
at a 1: 200 dilution. For visualization, an anti-mouse IgG-HRP
(Dako) conjugate was applied. Images were collected with a stereo-
microscope M205 FA equipped with an ICD camera from Leica.
Morpholino Oligos, RNA Injections, and
Embryological Methods
Two 25 bp Morpholino (MO) antisense oligomers, CS1 and CS2,
for zebrafish chsy1were obtained fromGene Tools; their sequences
are given in Table S4. MOs were resuspended in sterile water to
a concentration of 3 mM according to the manufacturer’s instruc-
tions. Embryos were injected at the 1 cell stage with 1 nl consistingJournal of Human Genetics 87, 768–778, December 10, 2010 769
of 0.2 nM CS1 and 1 nM CS2. Protocols for injections, whole-
mount in situ hybridization, and alcian blue staining can be found
at our laboratory’s website. A ZeissAxioplan microscope equipped
with a Zeiss AxioCam HRc was used for capturing images of
embryos. Pictures were assembled with Photoshop CS5.Results
A Frameshift Mutation in CHSY1 Is Identified
by Homozygosity Mapping and High-Throughput
Sequencing
Homozygosity mapping was performed on a Jordanian
consanguineous family consisting of two unaffected
parents (I:1 and I:2, Figure 1A), two affected children
(II:2 and II:3, Figure 1A), and one unaffected sibling (II:1,
Figure 1A). The clinical synopsis included congenital skel-
etal anomalies most evident on the hands and feet,
symmetrical and bilateral preaxial brachydactyly, micro-
gnathia, short stature, and variable degrees of learning
disability (Figures 1B–1D; see also Figure S1). X-ray exami-
nations revealed unified capitate and hamate bones and
partial duplication of proximal phalanges of digits 1 to 3,
suggestive of hyperphalangism (Figures 1C and 1D). The
clinical features of the two index cases in this study match
those described earlier by Dr. Samia Temtamy in another
inbred family from Egypt.11 On the basis of their compar-
ison (Figure S1), we reason that this Jordanian family
might represent another case of Temtamy Preaxial Brachy-
dactyly Syndrome (MIM 605282).
Genotyping of the five individuals on 610k Illumina SNP
arrays and subsequent identical-by-descent mapping
revealed four candidate regions totaling 16.8 Mb on chro-
mosomes 3, 5, 12, and 15 (Figure 1E). To screen the 177
candidate genes in these regions for mutations, we em-
ployed a targeted genomic loci capture12 followed by
high throughput resequencing (Figure 1F). In one affected
proband, 224 genomic mismatches were identified; of
these, two were homozygous and located in the coding
region of HTLF (MIM 143089) and CHSY1 (Table S1). The
HLTF mutation did not cosegregate with the disease in
the family. The nonsense mutation in CHSY1, caused by
a 1 bp deletion (Figure 1F), was inherited according to
the autosomal-recessive pattern inferred by this pedigree.
Because CHSY1 lies at the telomeric end of chromosome
15q, hemizygous deletions of CHSY1 occur in patients
with chromosome 15q26-qter Deletion Syndrome (MIM
612626);13 these distinct genetic diseases share some
common phenotypes, which are compared in Figure S1.
CHSY1 encodes chondroitin synthase 1, an evolution-
arily conserved sugar-synthesizing enzyme present both
in invertebrates and vertebrates (Figure 1G). Human
CHSY1, and its paralogous protein CHSY3 (MIM
609963), consists of a carboxy-terminal type-A glycosyl-
transferase catalytic site and an N-terminal Fringe
domain.14,15 When aligned to the three canonical FRINGE
proteins, i.e., LUNATIC (MIM 602576), MANIC (MIM
602577), and RADICAL (MIM 602578) FRINGE, the770 The American Journal of Human Genetics 87, 768–778, DecembCHSY1 and CHSY3 proteins show conservation of the
DXD motif, which is required for the glycosyltransferase
activity of FRINGE enzymes (Figure 1H).16,17The CHSY1 Frameshift Mutation Abolishes CHSY1
Protein Synthesis and Depletes Chondroitin Sulfates
in Patients
The biallelic one-base cytosine deletion in codon 32 of the
ORF of CHSY1 (c.96 del) introduces a frameshift leading to
a premature stop codon 2 amino acids downstream at
position 34 (p.Glu33SerFSX1). This nonsense mutation is
predicted to yield a severely truncated CHSY1 protein
missing both its catalytic domains (Figure 2A). To confirm
the absence of CHSY1 in affected individuals, we isolated
and cultured dermal fibroblasts from the male proband
(II:2) and his noncarrier unaffected sibling (II:1). CHSY1,
of the expected molecular weight, i.e, 88 kDa, was detected
by immunoblotting in nonreducing conditions in the
supernatant of primary fibroblasts but was undetectable
in that of mutant fibroblasts (Figure 2B). In reducing
conditions, CHSY1 migrated at 60 kDa, suggesting that
the mature secreted protein might comprise two or more
peptides linked by disulfide bridges. It is noteworthy that
soluble CHSY1 was found to accumulate in the superna-
tant of primary human fibroblast cultures, whereas its
primary amino acid sequence does not target it a priori
for secretion. In support of our finding, CHSY1 was previ-
ously reported to be the most prominent extracellular
protein in the conditioned medium of co-cultures
involving myeloma cells and osteoclasts;18 hence, CHSY1
might be processed for secretion in the Golgi via shedding
of its N-terminal transmembrane domain (Figure 2A). This
is in contrast to canonical FRINGE enzymes, which are
known to reside in the cis-Golgi and not in the extracel-
lular milieu unless overexpressed.16
CHSY1 is pivotal to the biosynthesis of chondroitin
sulfates (CSs), which belong to the glycosaminoglycans
(GAGs), consisting of alternating glucuronic acid (GlcUA)
and N-acetyl galactosamine (GalNAc) residues. Once
synthesized, CSs are covalently bound to side chains of
extracellular proteoglycans. CHSY1 possesses both the
glucuronyltransferase II and N-acetylgalactosaminyl-trans-
ferase II enzymatic activities necessary for the synthesis of
the repeating disaccharide unit of CS.14 To determine the
impact of the loss of CHSY1 activity on the deposition
and distribution of CSs, immunohistochemistry on
patients’ skin sections was performed with a monoclonal
antibody directed at CS groups. Lower levels of CS in the
stratum corneum, stratum germinativum, and dermal
layers of the affected patient (II:2) relative to the control
(II:1) were seen (Figures 2C and 2D). CS levels were also
reduced in cultures of CHSY1-deficient primary fibroblasts
(data not shown), which had a slower growth rate and
different cell morphology than control fibroblasts (Figures
2C and 2D, insets). Taken together, our data suggest the
CHSY1 is a secreted enzyme involved in the synthesis ofer 10, 2010
Figure 1. Phenotypic Characteristics of Investigated Patients with Syndromic Recessive Brachydactyly Caused by a Frameshift Muta-
tion in CHSY1
(A) Affected children, male (II:2) and female (II:3), were born to first-cousin parents (I:1 and I:2) with one unaffected child (II:1).
(B) Head shot of affected boy (II:2) with protruding eyes, downward turn of mouth, and micrognathia.
(C) X-ray radiograph of male proband’s right hand when he was 8 years of age, showing partial duplications of proximal phalanges in
digits 1, 2, and 3 (inset: hand photograph).
(D) X-ray radiograph and picture of male proband’s right foot showing severe skeletal anomalies. The big toe exhibits short and dupli-
cated metatarsals and proximal phalanges. The second and fourth proximal phalanges are duplicated as well.
(E) Homozygosity mapping delineated four candidate loci totaling 19 cM on chromosomes 3, 5, 12, and 15.
(F) Genomic capturing and resequencing of candidate loci revealed a 1 bp deletion in CHSY1 on chromosome 15; this deletion caused an
early-termination stop codon at amino acid 34 of the CHSY1 enzyme.
(G) Phylogenetic tree showing conservation of CHSY1 across invertebrate and vertebrate species.
(H) The CHSY1 enzyme and its paralogous protein CHSY3 bear a Fringe domain that aligns to that of canonical MANICAL (MFNG),
RADICAL (RFNG), and LUNATIC (LFNG) FRINGE. A conserved DDD motif is highlighted with a star.CS moieties and that the reported nonsense mutation
leads to a loss of function in humans.
Loss of CHSY1 Activity Triggers Massive NOTCH
Activation in Patients’ Cells
To gain insights into the pathogenesis of the disease, we
sought to determine how secreted CHSY1 activity was
coupled to known extracellular proteins causing brachy-
dactyly in mice and humans.1,19 Out of 16 genes whoseThe Americanmutations result in brachydactyly,1,19 CHSY1 transcripts
were most correlated with those of the NOTCH2 (MIM
600275) and NOTCH1 (MIM 190198) receptors (Table
S2). Because CHSY1 bears a Fringe domain, which modu-
lates ligand interaction with NOTCH receptors,20 and
because NOTCH2 activation was shown to be regulated
by CHSY1 levels in co-cultures of myeloma cells and oste-
oclasts,18 we assessed components of the NOTCH
signaling pathway in patients’ primary fibroblast cellJournal of Human Genetics 87, 768–778, December 10, 2010 771
Figure 2. Loss of CHSY1 Results in Depletion of Chondroitin Sulfates and Activation of NOTCH Signaling
(A) The full-length CHSY1 (WT) consists of a type II transmembrane domain, a Fringe motif, and a type A glycosyltransferase domain.
The frameshift mutation (MUT) deletes more than 95% of CHSY1, including both of its putative catalytic sites, marked with an asterisk.
(B) CHSY1 is found in the supernatant of primary fibroblast cultures from unaffected sibling II:1 (WT) but not from that of the affected
proband II:2 (MUT).
(C and D) Depletion of CS, a product of the CHSY1 enzyme, is observed by immunohistochemistry in the skin of affected II:2 (D) versus
unaffected sibling II:1 (C). CHSY1-deficient primary fibroblasts (D, inset) have aberrant morphologies and slower growth rates than
control fibroblasts (C, inset).
(E) Massive upregulation of JAG1 and HES1 in affected primary fibroblasts, indicative of abnormally high NOTCH signaling, is observed
by q-PCR analysis. Mutant CHSY1 transcripts were not subjected to nonsense-mediated decay. Upregulation of NOTCH signaling was
reversed by the addition of a g-secretase inhibitor.
(F) Overexpression of intact CHSYI, but not of a Fringe-dead CHSY1 D171A mutant, can reverse NOTCH activation in CHSY1-deficient
fibroblasts.
(G) Abnormally high JAG1 protein production is seen in CHSY1-deficient fibroblasts (lanes 3 and 4) compared to control fibroblasts
(lanes 1 and 2). Addition of a g-secretase inhibitor rescues NOTCH activationmeasured by HES1 levels in CHSY1-deficient cells (compare
lanes 3 and 4).
Values in (E) and (F) represent means5 SE of data from three independent experiments, *p < 0.05.cultures. By quantitative PCR, relative transcript abun-
dance of JAG1 (MIM 601920), a NOTCH ligand, and
HES1 (MIM 139605), an immediate target of NOTCH,
were found to be significantly upregulated—14-fold and
18-fold, respectively—in comparison to unaffected cells
(Figure 2E). Levels of NOTCH1 and NOTCH2 were moder-
ately increased. Endogenous CHSY1 transcripts were found
to be higher in CHSY1 null cells, suggesting that the
reported frameshift does not trigger the surveillance
nonsense-mediated-decay pathway. Addition of a g-secre-
tase inhibitor, blocking NOTCH signaling at the receptor
level,21 partially rescued NOTCH over-activation in772 The American Journal of Human Genetics 87, 768–778, DecembCHSY1-deficient patient cells (Figure 2E). The remarkable
transcriptional upregulation of JAG1 and HES1 was
confirmed at the protein level by immunoblotting
(Figure 2G); an average 10-fold increase in JAG1 protein
synthesis was seen in primary CHSY1-deficient fibroblasts
at various passages (compare lanes 1 and 3, Figure 2G).
Likewise, inhibiting g-secretase activity partially rescued
HES1 levels in CHSY1-deficient cells. JAG1 levels were
also reduced, albeit to a lesser extent (compare lanes 3
and 4, Figure 2G).
Next, to determine whether CHSY1-mediated NOTCH
inhibition required the Fringe domain, we carried outer 10, 2010
Figure 3. CHSY1 Knockdown Promotes NOTCH Signaling and Enhances Osteogenesis In Vitro
(A) CHSY1 siRNA in human fetal osteoblasts (hFOB) cells achieved 75% knockdown with concurrent 6-fold upregulation of HES1, an
immediate NOTCH target. Other genes belonging to the NOTCH pathway were moderately but significantly upregulated.
(B) CHSY1 siRNA triggered upregulation of osteogenic markers, indicative of premature differentiation, whereas proliferation markers
were downregulated.
(C) CHSY1 siRNA in human glioblastoma cells (T98G) achieved 87% knockdown and a paralleled 10-fold upregulation of HES1 and
24-fold increase in JAG2 transcription.
Values in (A)–(C) represent means5 SE of data from three independent experiments, *p < 0.05.rescue experiments in patients’ primary cells. NOTCH up-
regulation in CHSY1-deficient cells could only be reversed
by transfection of wild-type human CHSY1 but not of
a D171A Fringe catalytically dead mutant construct17
(Figure 2F), indicating that CHSY1 requires an intact Fringe
domain to execute its function. Together, these results
argue that secreted CHSY1, via its Fringe domain, exerts
NOTCH inhibitory activity in human primary skin fibro-
blasts and that its absence triggers massive JAG1 protein
synthesis.
CHSY1 Knockdown by siRNA in Human Osteoblast
Progenitor Cells Triggers NOTCH Activation and
Premature Osteogenic Differentiation
To address the ossification anomalies, we then modeled
loss of CHSY1 by siRNA in a human fetal osteoblast
(hFOB) progenitor cell line (Figures 3A and 3B). CHSY1
siRNA, which achieved more than 75% knockdown effi-
ciency, resulted in markedly increased NOTCH signaling,
as indicated by the 6-fold increase in the abundance of
HES1 transcripts (Figure 3A); levels of JAG1, JAG2 (MIM
602570), and NOTCH1 were moderately but significantly
increased. Concurrent with NOTCH upregulation, markers
of osteogenic differentiation such as ALPL (MIM 171760),
BSPH1 (MIM 147563), BGLAP (MIM 112260), OSX (MIM
606633), and RUNX2 (MIM 600211) were significantly
augmented, whereas markers of proliferation such asThe AmericanCCND1 (MIM 168461) and C-MYC (MIM 190080) were
reduced (Figure 3B). Alkaline phosphatase activity was
increased by 40% (data not shown). Taken together, these
results suggest that CHSY1 knockdown, which leads to
NOTCH activation, suffices to bring about premature, or
enhanced, osteogenic differentiation in a hFOB progenitor
cell line. These in vitro data provide a possible patho-
mechanism for the observed accessory bones and hyper-
phalangism seen in the two affected children.
To substantiate CHSY1’s specificity on NOTCH
signaling, we repeated RNAi knockdown in a human
neural glioblastoma cell line (Figure 3C). Unexpectedly,
JAG2, but not JAG1 as in primary patient fibroblasts, was
greatly increased (24-fold). As in hFOB and patient primary
cells, HES1 levels were also upregulated, indicative of
robust NOTCH activation. Together, these in vitro experi-
ments argue that CHSY1 bears widespread repressive
activity on NOTCH signaling and that this inhibition is
likely to be gene and tissue specific.
Loss of Function of chsy1 in Zebrafish Embryos
Impairs Skeletogenesis and Leads to Increased Notch
Signaling
To model, in vivo, the birth defects observed in CHSY1
mutant individuals, we next performed chsy1 morpholino
(MO) injections in developing zebrafish embryos (Figure 4).
To block translation of maternal and zygotic chsy1Journal of Human Genetics 87, 768–778, December 10, 2010 773
Figure 4. chsy1 Knockdown in Zebrafish Embryos Affects Segmentation and Increases Notch Signaling
(A) Six-day-old wild-type embryo.
(B) Six-day-old chsy1 MO-injected embryo with a protruding mouth-piece, eyes joined at the midline, and arched trunk.
(C) Six-day-old chsy1 MO-injected embryo rescued with 200 pg of human CHSY1 mRNA.
(D) Ten-somite-stage wild-type embryo stained with pax2.1marking the optic stalk (os), midbrain-hindbrain boundary (mhb), otic plac-
odes (op), and pronephric duct (pd) and with papc marking the pre-somitic mesoderm (psm) and the tailbud (tb).
(E) Ten-somite stage chsy1morphant embryo displays a fused anterior eyefield, near-absent isthmic organizer, and otic placodes marked
by pax2.1. Aberrant segmentation of the pre-somitic mesoderm and lack of papc staining in the tailbud indicate anomalies in somito-
genesis.
(F and F0) Wild-type (F) and chsy1morphant (F0) 24 hpf embryos stained for the Notch ligand jag2. Note ectopic or delayed clearance of
jag2 expression in trunk somites.
(G and G0) Wild-type (G) and chsy1morphant (G0) 24 hpf embryos stained for the Notch ligand deltaC. Note the enhanced expression in
presomitic mesoderm at the tailbud level.
(H and H0) Wild-type (H) and chsy1morphant (H0) 24 hpf embryos that were stained with lim1 and whose expression is downregulated
by Notch signaling. The loss of lim1 expression in head and trunk structures indicates greater-than-normal Notch signaling in chsy1mor-
phants relative to controls.transcripts, we used two MOs against chsy1, as previously
described.22 chsy1 was ubiquitously present from the un-
fertilized oocyte to the end of somitogenesis (Figure S2).
By day two, its expression was limited to head structures;
there was prominent expression in the inner ear and
diffuse expression in developing chondrocytes of the
pectoral-fin bud (Figure S2J). Compared to wild-type
siblings at 6 days (Figure 4A), morphant chsy1 embryos
developed into stunted larvae with severe eye anomalies
and cartilage and pectoral-fin defects (Figure 4B). The spec-
ificity of the MOs was addressed by rescue experiments;
chsy1 MOs were coinjected with human CHSY1 mRNA at
the one-cell stage. In 87% (n ¼ 149/171) of the coinjected
embryos, chsy1 morphant phenotypes were rescued
(Figure 4C; see also Table S3). At the ten-somite stage,
chsy1 morphants exhibited obvious segmentation anoma-
lies marked by poorly segmented presomitic mesoderm
and absence of papc expression in the tailbud (Figures 4D
and 4E). Anterior defects in chsy1 morphants comprised
a single anterior eyefield, as opposed to split eyefields in
control embryos, and reduced pax2.1 expression in otic774 The American Journal of Human Genetics 87, 768–778, Decembplacodes and in themidbrain-hindbrain boundary (Figures
4D and 4E). By 24 hpf, expression of the two notch ligands
jag2 and deltaC was increased in chsy1 morphants as
compared to wild-type embryos (Figures 4 F–4G0), jag2
was found to be ectopically expressed in trunk paraxial
mesoderm, indicative of impaired segmentation, whereas
deltaC levels in tailbud and presomitic mesoderm were
enhanced (Figures 4F–4G0). We next assessed lim1, a target
of Notch signaling whose expression is repressed by the
Notch pathway.23 Reflecting greater-than-normal Notch
activity in chsy1 morphants, lim1 expression was visibly
dampened in head and trunk structures relative to those
of control embryos (Figures 4H and 4H0). Collectively,
these results indicate that chsy1 activity is essential for
toning down Notch signaling across various embryonic
structures during zebrafish development.
Zebrafish chsy1 Morphant Embryos Partially
Phenocopy Human Disorder
By day 5, zebrafish chsy1 morphant embryos exhibited
major skeletal anomalies encompassing severe jawer 10, 2010
Figure 5. Phenotypes of chsy1 Zebrafish Morphant Embryos Partially Phenocopy Human Disorder
(A) Ventral view of alcian-blue-stained 5-day-old wild-type embryo.
(B) Three representative chsy1 MO-injected embryos exhibiting variable phenotypic penetrance, including skeletal anomalies (arrow-
heads), massive overgrowth of retinas, and pectoral-fin defects ranging from asymmetric development to unilateral or bilateral aplasia
(asterisks).
(C) Percentage of eyes and pectoral-fin defects scored in chsy1MO compared to wild-type embryos. (Asym., asymmetric; Abst., absent).
(D) Hematoxylin and Eosin (H&E) head sections of 5-day-old wild-type embryo.
(E) H&E sections throughmidline-joining retinas of chsy1morphant embryos at 5 days of development. Note hyperplasia of pigmented
epithelium (pe) and increased cell numbers in the ganglion cell layer (gcl).
(F and F0) Pectoral fin of a 6-day-old wild-type embryo. (F0) High-magnification view of the endoskeletal disc showing cartilage tissue with
monolayered chondrocytes stained with alcian blue.
(G and G0) Pectoral fin of a mildly affected 6-day-old chsy1MO-injected embryo exhibiting hypoplasia of the endoskeletal disc (ed) rela-
tive to the fin blade (fb). (G0) High-magnification view of cartilage tissue with multilayered disorganized chondrocytes in the endoskel-
etal disc of chsy1 morphant embryo stained with alcian blue.
(H) Lateral view of 5-day-old chsy1 morphant embryos with severe jaw hypoplasia and eye defects.
(I) Ethmoid plate of a 5-day-old wild-type embryo stained with alcian blue.
(J) Irregularly shaped ethmoid plate of a 5-day-old chsy1 morphant embryo.
(K) Affected girl (II:3), showing bilateral macrophthalmia and blue sclera.
(L) Color fundus photographs of affected girl (II:3) at 6 years of age. The girl had bilateral tilted eye discs and normal visual acuity in each
eye.hypoplasia, impaired pectoral-fin development, and prom-
inent eyes (Figures 5A–5G0). The anterior paired pectoral
fins, which are analogous to the mammalian forelimbs,
were affected in 65% (n¼ 94/144) of MO-injected embryos
(Figure 5C). Anomalies in the development of the pectoral
fins ranged from pronounced asymmetries to unilateral or
bilateral aplasia (Figures 5A and 5B). Bright-field images ofThe Americandissected pectoral fins from mildly affected chsy1-mor-
phant embryos revealed structural anomalies of the endo-
skeletal disc, a structure analogous to the bones found in
higher pentadactyl vertebrates. In contrast, fin blades, of
which no equivalent tissue exists in mammals, were
relatively normal in morphants (Figures 5F and 5G).
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in the chsy1-morphant limb buds revealed a disorganized,
multilayered tissue (Figure 5G0) as opposed to the mono-
layer tissue organization in wild-type limb buds
(Figure 5F0). Other remarkable cartilage defects, including
disgenesis of the ethmoid plate (Figures 5I and 5J), in the
neurocranium resulted in a protruding-snout, ‘‘seahorse’’
phenotype (Figure 5H).
Unexpectedly, eye anomalies were also present in more
than 50% (n ¼ 84/144) of morphant embryos (Figures
5A–5E). In extreme cases, chsy1 morphants developed
four eyes resembling complete bilateral retinal duplications
(Figure 5B). Histological examination showed instead one
pair of overgrown retinas, which joined at the midline.
No lens duplication was recorded. chsy1 morphant eyes
presented with the expected retinal cell layers but had
augmented cell numbers in the ganglion cell layer and the
pigmented epithelium (Figures 5D and 5E). This prominent
eye phenotype found in chsy1morphant fish prompted us
to re-examine our two human index cases for possible
ocular anomalies. Fundoscopic evaluations did not reveal
altered retinal thickness, but we noted that both probands
exhibited macrophthalmia accompanied by bilateral blue
sclera, remnants of pupillarymembrane over the crystalline
lens, and tilted optic discs in both eyes (Figures 5K and 5L).
This suggests thatCHSY1mayplaya role ineyemorphogen-
esis in humans as well. Thus, knockdown of chsy1 in zebra-
fish embryos revealed a conserved role for CHSY1 during
embryogenesis in vertebrates. The phenotypes observed
upon knockdown of chsy1 in fish partially phenocopy the
human disorder, revealing a conserved role for CHSY1 in
skeletal development and limb morphogenesis during
vertebrate embryogenesis.Discussion
In summary, loss of CHSY1 is a cause of recessive syn-
dromic brachydactyly and evokes phenotypes that overlap
with mutations in the BMP, GDF, and Hedgehog path-
ways.1 The pathophysiological basis of this syndrome
appears to be enhanced, or premature, ossification—
possibly driven by greater-than-normal NOTCH
signaling—leading to congenital skeletal anomalies most
obvious in digits. This is consistent with studies performed
in mice, where appropriate Notch signaling was found to
be essential for the normal progression of chondrocyte
differentiation into bone in the developing appendicular
and axial skeletal elements.24 The particular splitting of
proximal phalanges in digits 1, 2, and 3 in this syndrome
might be explained by double epiphyses growing along
the longitudinal, rather than horizontal, axis. An analo-
gous situation has been reported in Brachydactyly type
A2, caused by mutations in GDF5, where a single epiph-
ysis, albeit turned, results in a triangular bone.3
At the molecular level, we propose that CHSY1 inhibits
theNOTCHpathway in the extracellular space via its Fringe
domain. The aberrant production of JAG1 protein in776 The American Journal of Human Genetics 87, 768–778, Decembhuman CHSY1-deficient fibroblasts raises the possibility
that ectopic NOTCH signaling mediated by JAG1 during
embryogenesis could in part be responsible for the birth
defects specific to this syndrome. Control of CHSY1 activity
in a tissue-specificmannermay therefore constitute a thera-
peutic target for patients with Alagille syndrome (MIM
118450) caused by JAG1 haploinsufficiency.25,26
We speculate that CHSY1, which needs an intact Fringe
domain to exert its NOTCH inhibitory activity, might
post-translationally modify NOTCH-related proteins.
However, substantiating that NOTCH receptors, or their
ligands, are actual substrates of CHSY1 will require
biochemical evidence. If so, CSs, of which two paralogs
exist in the human genome, might function as a new class
of FRINGE enzymes controlling NOTCH output during
developmental, physiological, or pathological processes.
Concurrently and alternatively, CHSY1 loss, which leads
to reduced CS moieties and therefore altered proteoglycan
synthesis, might affect other signaling pathways associated
with brachydactylies. When one considers that sulfated
glycans canmodulate FGF/FGFR interactions, that CS affect
IHH signaling,27,28 and that both FGF and IHH can in turn
regulate BMP/GDF,29 it is conceivable that reduced CS
might impede digit development by altering these path-
ways, instead of or in addition to NOTCH signaling.
The in vivo knock-down experiments carried out in
zebrafish embryos confirmed chsy1’s role during skeleto-
genesis and unmasked its importance during eye develop-
ment. Emulating the results obtained in cell culture, Notch
over-activation, marked by jag2 upregulation and silencing
of lim1, in chsy1 morphant embryos argues that chsy1 is
also necessary for driving repression of Notch signaling
during development. It is noteworthy that chsy1morphant
embryos bear striking resemblance to the maternal zebra-
fish mutant pug described by the group of Mary Mullins.30
Pug mutants lack pectoral fins, have eyes joined at the
midline, and present with segmentation anomalies similar
to what is described here. It is therefore tempting to spec-
ulate that pugmight be a chsy1maternal mutant. Although
chsy1 and pug might not be allelic, these two genes might
instead delineate a common pathway controlling limb
patterning in addition to the oocyte-to-embryo transition.
In support of CHSY1’s putative role in the earliest stages of
development, RNA-interference-mediated depletion of
ChSy (paralogous to human CHSY1) in C. elegans triggers
cytokenesis reversal, and blocks cell divisions at the 2- to
4-cell stage.31 Should CHSY1’s role during oogenesis be
conserved in humans, we are aware that the reported
loss-of-function mutation in this study would only
unmask the zygotic function of CHSY1. In contrast, a bial-
lelic maternal mutation might lead to early embryonic
lethality, and signs of sterility in homozygous CHSY1
mutant women should hereafter be anticipated.
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